ACM
IBB icon

Anfield Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Anfield Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.94K Hold
47
– – ﹤0.01% 465
2025
Q4 		$7.93K Hold
47
– – ﹤0.01% 359
2025
Q3 		$6.79K Hold
47
– – ﹤0.01% 371
2025
Q2 		$5.95K Hold
47
– – ﹤0.01% 356
2025
Q1 		$6.01K Hold
47
– – ﹤0.01% 306
2024
Q4 		$6.21K Hold
47
– – ﹤0.01% 290
2024
Q3 		$6.84K Hold
47
– – ﹤0.01% 280
2024
Q2 		$6.45K Buy
+47
New +$6.27K ﹤0.01% 233

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Anfield Capital Management's IBB Position: Q1 2026 in Review

Anfield Capital Management held its iShares Biotechnology ETF (IBB) position steady in Q1 2026 at 47 shares worth $7.94K. The position accounts for ﹤0.01% of the portfolio, ranked #465.

Anfield Capital Management first reported a position in IBB in Q2 2024 and has held it in 8 quarters since. 921 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Anfield Capital Management held 47 shares of iShares Biotechnology ETF worth $7.94K as of Q1 2026.
  • Anfield Capital Management left its iShares Biotechnology ETF share count unchanged in Q1 2026.
  • iShares Biotechnology ETF made up ﹤0.01% of Anfield Capital Management's portfolio in Q1 2026, its #465 holding.
  • Anfield Capital Management first reported a position in iShares Biotechnology ETF in Q2 2024 and has held it in 8 quarters since.
  • 921 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.